

*Category of Adverse Events, by patient and overall*

	Treatment group				
	HLSCs 125,000 cells/ gram of liver	HLSCs 250,000 cells/ gram of liver		Overall	
	pz 01-001	pz 01-002	pz 01-003	events n (%)	subjects n (%)
<b>Total AEs</b>	<b>6</b>	<b>2</b>	<b>4</b>	<b>12</b>	<b>3 (100 %)</b>
<b>SOC</b> <i>PPT MedDRA</i>					
<b>Blood and lymphatic system disorders</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>1 (8.3%)</b>	<b>1 (33.3%)</b>
<i>Thrombocytosis</i>	<i>1</i>			<i>1</i>	<i>1</i>
<b>Epidermal and dermal conditions</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>2 (16.7%)</b>	<b>2 (66.7%)</b>
<i>Dermatitis</i>	<i>1</i>	<i>1</i>		<i>2</i>	<i>2</i>
<b>Eye disorder</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>1 (8.3%)</b>	<b>1 (33.3%)</b>
<i>Eyelid edema</i>	<i>1</i>			<i>1</i>	<i>1</i>
<b>Gastrointestinal disorders</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>1 (8.3%)</b>	<b>1 (33.3%)</b>
<i>Diarrhea</i>	<i>1</i>			<i>1</i>	<i>1</i>
<b>Gastrointestinal signs and symptoms</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>1 (8.3%)</b>	<b>1 (33.3%)</b>
<i>Vomiting</i>			<i>1</i>	<i>1</i>	<i>1</i>
<b>Nervous system disorders</b>	<b>1</b>	<b>0</b>	<b>1</b>	<b>2 (16.7%)</b>	<b>2 (66.7%)</b>
<i>Agitation neonatal</i>	<i>1</i>			<i>1</i>	<i>1</i>
<i>Tremor</i>			<i>1</i>	<i>1</i>	<i>1</i>
<b>Renal and urinary disorders</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>3 (25%)</b>	<b>3 (100%)</b>
<i>Urinary abnormalities</i> <i>Leukocyturia</i>	<i>1</i>			<i>1</i>	<i>1</i>
<i>Urinary tract infection</i>		<i>1</i>	<i>1</i>	<i>2</i>	<i>2</i>
<b>Skin and subcutaneous tissue disorders</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>1 (8.3%)</b>	<b>1 (33.3%)</b>
<i>Skin rash</i>			<i>1</i>	<i>1</i>	<i>1</i>